Cost-effectiveness of omadacycline versus moxifloxacin as the initial treatment for community-acquired bacterial pneumonia in China
Abstract
Abstract Introduction: Community-acquired bacterial pneumonia (CABP) remains a leading cause of hospitalization, morbidity, and mortality worldwide, with substantial clinical and economic burdens. Effective initial antibiotic therapy is critical to optimize patient outcomes and reduce healthcare costs. Omadacycline, a novel aminomethylcycline with broad-spectrum antibacterial activity and favorable pharmacokinetics, has been approved by the U.S. Food and Drug Administration for the treatment of CABP. Clinical studies have shown that omadacycline is non-inferior to moxifloxacin, a widely used respiratory fluoroquinolone, in terms of efficacy. However, the higher acquisition cost of omadacycline raises questions regarding its economic value, particularly in resource-limited healthcare systems such as China. Given the increasing emphasis on cost-effectiveness to guide formulary decisions, evaluating the economic viability of omadacycline relative to moxifloxacin is essential. Aim This study evaluated the cost-effectiveness of omadacycline versus moxifloxacin as initial treatment for CABP in China. Method A decision-tree model was constructed using TreeAge Pro 2020 to assess sequential intravenous (IV)-to-oral omadacycline versus moxifloxacin in adult patients with non-severe CABP. Parameter values were obtained from published literature, public databases, and clinician surveys. Incremental cost-effectiveness ratios (ICERs) were calculated, and sensitivity analyses were…
Read the paper
Related studies
- Structural and topological analysis of thiosemicarbazone-based metal complexes: computational and experimental study of bacterial biofilm inhibition and antioxidant activity
- Toward better cures for Mycobacterium abscessus lung disease
- Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing
- Design, Synthesis and In vitro Antitubercular Effect of New Chalcone Derivatives Coupled with 1,2,3‐Triazoles: A Computational Docking Techniques
- Upregulation of pmrA, pmrB, pmrC, phoQ, phoP, and arnT genes contributing to resistance to colistin in superbug Klebsiella pneumoniae isolates from human clinical samples in Tehran, Iran
- Whole-genome sequencing of clinical isolates of Citrobacter Europaeus in China carrying blaOXA−48 and blaNDM−1
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.